Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.14.11.53: mRNA N6-methyladenine demethylase

This is an abbreviated version!
For detailed information about mRNA N6-methyladenine demethylase, go to the full flat file.

Word Map on EC 1.14.11.53

Reaction

N6-methyladenine in mRNA
+
2-oxoglutarate
+
O2
=
adenine in mRNA
+
formaldehyde
+
succinate
+
CO2

Synonyms

AlkB homolog 5, ALKBH10B, ALKBH5, ALKBH5 demethylase, ALKBH9B, alkylation repair homolog protein 5, fat mass and obesity-associated enzyme, fat mass and obesity-associated protein, FTO, m6A mRNA demethylase, m6A RNA demethylase, m6A-RNA demethylase, N6-methyladenosine demethylase, RNA N6-methyladenine demethylase

ECTree

     1 Oxidoreductases
         1.14 Acting on paired donors, with incorporation or reduction of molecular oxygen
             1.14.11 With 2-oxoglutarate as one donor, and incorporation of one atom of oxygen into each donor
                1.14.11.53 mRNA N6-methyladenine demethylase

Disease

Disease on EC 1.14.11.53 - mRNA N6-methyladenine demethylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of CYR61 mRNA.
Adenocarcinoma
m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling.
Adenocarcinoma of Lung
ALKBH5-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia.
ALKBH5-mediated m6A demethylation of lncRNA RMRP plays an oncogenic role in lung adenocarcinoma.
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
Adenoma, Oxyphilic
The N6 -methyladenosine (m6 A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma.
Adenomyosis
m6A RNA Methylation Regulators Contribute to Eutopic Endometrium and Myometrium Dysfunction in Adenomyosis.
Aneurysm, Dissecting
KIAA1429 and ALKBH5 Oppositely Influence Aortic Dissection Progression via Regulating the Maturation of Pri-miR-143-3p in an m6A-Dependent Manner.
Arthritis, Rheumatoid
Decreased ALKBH5, FTO, and YTHDF2 in Peripheral Blood Are as Risk Factors for Rheumatoid Arthritis.
Atherosclerosis
Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice.
Bacterial Infections
Circular RNA circZbtb20 maintains ILC3 homeostasis and function via Alkbh5-dependent m6A demethylation of Nr4a1 mRNA.
Bone Resorption
Circ_0008542 in osteoblast exosomes promotes osteoclast-induced bone resorption through m6A methylation.
Downregulated fat mass and obesity-associated protein inhibits bone resorption and osteoclastogenesis by nuclear factor-kappa B inactivation.
Brain Neoplasms
ALKBH5 Drives FOXM1 Expression to Promote Brain Tumor Stem Cell Growth.
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Breast Neoplasms
ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.
Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin.
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA.
Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells.
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
Carcinogenesis
A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Active Site Breathing of Human Alkbh5 Revealed by Solution NMR and Accelerated Molecular Dynamics.
ALKBH5 Drives FOXM1 Expression to Promote Brain Tumor Stem Cell Growth.
ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.
ALKBH5-mediated m6A demethylation of lncRNA RMRP plays an oncogenic role in lung adenocarcinoma.
Autophagy of the m6A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis.
Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma.
Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer.
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
FTO modifies the m6A level of MALAT and promotes bladder cancer progression.
m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling.
N 6-methyladenosine binding induces a metal-centered rearrangement that activates the human RNA demethylase Alkbh5.
N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma.
Novel insights into the interplay between m6A modification and noncoding RNAs in cancer.
RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-?B pathway.
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5.
Carcinoma
A positive feedback loop between AlkB homolog 5 and miR-193a-3p promotes growth and metastasis in esophageal squamous cell carcinoma.
ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m6A-dependent manner.
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
m6 A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis.
m6A demethylase ALKBH5 suppression contributes to esophageal squamous cell carcinoma progression.
N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1? signalling axis.
N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.
The N6 -methyladenosine (m6 A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma.
Carcinoma, Hepatocellular
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1.
Carcinoma, Non-Small-Cell Lung
N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability.
Carcinoma, Ovarian Epithelial
ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.
Carcinoma, Renal Cell
ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m6A-dependent manner.
N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1? signalling axis.
The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.
The N6 -methyladenosine (m6 A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma.
Carcinoma, Squamous Cell
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
Cardiovascular Diseases
RNA Modification by m6A Methylation in Cardiovascular Disease.
Cholangiocarcinoma
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
Colitis
m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity.
Colonic Neoplasms
ALKBH5 Holds Prognostic Values and Inhibits the Metastasis of Colon Cancer.
ALKBH5 promotes colon cancer progression by decreasing methylation of the lncRNA NEAT1.
Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma.
RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
Colorectal Neoplasms
FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis.
FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell.
Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators.
COVID-19
Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication.
Dehydration
Alpha-ketoglutarate-dependent dioxygenase homolog 10B, an N6 -methyladenosine mRNA demethylase, plays a role in salt stress and abscisic acid responses in Arabidopsis thaliana.
Diabetes Mellitus
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Diabetes Mellitus, Type 2
Association of Metabolites with Obesity and Type 2 Diabetes Based on FTO Genotype.
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Human and Arabidopsis alpha-ketoglutarate-dependent dioxygenase homolog proteins-New players in important regulatory processes.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
Digestive System Neoplasms
Emerging Roles of N6-Methyladenosine Demethylases and Its Interaction with Environmental Toxicants in Digestive System Cancers.
Encephalomyelitis
m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity.
Endometrial Neoplasms
ALKBH5 regulates IGF1R expression to promote the Proliferation and Tumorigenicity of Endometrial Cancer.
Effects of m6A RNA methylation regulators on endometrial cancer.
Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway.
Esophageal Neoplasms
N6-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression.
Esophageal Squamous Cell Carcinoma
A positive feedback loop between AlkB homolog 5 and miR-193a-3p promotes growth and metastasis in esophageal squamous cell carcinoma.
m6 A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis.
m6A demethylase ALKBH5 suppression contributes to esophageal squamous cell carcinoma progression.
Exanthema
Decreased Peripheral Blood ALKBH5 Correlates with Markers of Autoimmune Response in Systemic Lupus Erythematosus.
Glioblastoma
3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line.
ALKBH5 Drives FOXM1 Expression to Promote Brain Tumor Stem Cell Growth.
ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.
m6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells.
Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis.
Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
Glioma
A Risk Signature Consisting of Eight m6A Methylation Regulators Predicts the Prognosis of Glioma.
ALKBH5 Promotes the Proliferation of Glioma Cells via Enhancing the mRNA Stability of G6PD.
miRNA-193a-3p Regulates the AKT2 Pathway to Inhibit the Growth and Promote the Apoptosis of Glioma Cells by Targeting ALKBH5.
The Emerging Roles of RNA Modifications in Glioblastoma.
The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells.
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Graves Disease
Inclusion of ALKBH5 as a candidate gene for the susceptibility of autoimmune thyroid disease.
Hepatoblastoma
ALKBH5 Gene Polymorphisms and Hepatoblastoma Susceptibility in Chinese Children.
Hirschsprung Disease
m6A demethylase ALKBH5 suppresses proliferation and migration of enteric neural crest cells by regulating TAGLN in Hirschsprung's disease.
Infarction, Middle Cerebral Artery
N6-methyladenosine demethylases Alkbh5/Fto regulate cerebral ischemia-reperfusion injury.
Infections
A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
m6A mRNA Methylation Regulates Epithelial Innate Antimicrobial Defense Against Cryptosporidial Infection.
Infertility
Sequencing of FTO and ALKBH5 in men undergoing infertility work-up identifies infertility-associated variant and two missense mutations.
Insulin Resistance
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Leukemia
Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis.
Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors.
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Leukemia, Myeloid
Rubbing Out Leukemia Stem Cells by Erasing the Eraser.
Leukemia, Myeloid, Acute
Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis.
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
Liver Neoplasms
Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer.
Lung Neoplasms
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
IL-37 Confers Anti-Tumor Activity by Regulation of m6A Methylation.
m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.
N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability.
Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.
Lupus Erythematosus, Systemic
Decreased Peripheral Blood ALKBH5 Correlates with Markers of Autoimmune Response in Systemic Lupus Erythematosus.
The study of METTL14, ALKBH5, and YTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus.
Lymphatic Metastasis
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Lymphoma, B-Cell
MYC promotes cancer progression by modulating m6 A modifications to suppress target gene translation.
Melanoma
ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
ALKBH5-mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma.
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators.
Metabolic Diseases
NADP modulates RNA m6A methylation and adipogenesis via enhancing FTO activity.
Metabolic Syndrome
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Mouth Neoplasms
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
mrna n6-methyladenine demethylase deficiency
ALKBH5-Modified HMGB1-STING Activation Contributes to Radiation Induced Liver Disease via Innate Immune Response.
m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity.
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
Myocardial Infarction
ALKBH5 regulates cardiomyocyte proliferation and heart regeneration by demethylating the mRNA of YTHDF1.
Neoplasm Metastasis
A positive feedback loop between AlkB homolog 5 and miR-193a-3p promotes growth and metastasis in esophageal squamous cell carcinoma.
ALKBH5 Holds Prognostic Values and Inhibits the Metastasis of Colon Cancer.
ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1.
ALKBH5-mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma.
FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis.
Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells.
m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
The biological function of m6A demethylase ALKBH5 and its role in human disease.
Neoplasms
3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line.
A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
ALKBH5 Gene Polymorphisms and Hepatoblastoma Susceptibility in Chinese Children.
ALKBH5 Holds Prognostic Values and Inhibits the Metastasis of Colon Cancer.
ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2?-Mediated Glycolysis.
ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation.
ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m6A-dependent manner.
ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1.
ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.
ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
ALKBH5-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia.
ALKBH5-mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma.
ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B.
Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases.
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.
Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression.
Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression.
Development and validation of a m6A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma.
Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer.
Emerging Roles of N6-Methyladenosine Demethylases and Its Interaction with Environmental Toxicants in Digestive System Cancers.
Expression patterns and prognostic value of m6A-related genes in colorectal cancer.
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis.
Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA.
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA.
Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma.
Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival.
Identification of Specific N6-methyladenosine RNA Demethylase FTO Inhibitors by Single Quantum Dot-Based FRET Nanosensor.
Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability.
m6 A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis.
m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling.
m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
m6A demethylase ALKBH5 suppression contributes to esophageal squamous cell carcinoma progression.
m6A demethylase FTO induces NELL2 expression by inhibiting E2F1 m6A modification leading to metastasis of non-small cell lung cancer.
m6A RNA methylation regulators have prognostic value in papillary thyroid carcinoma.
Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis.
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
N 6-methyladenosine binding induces a metal-centered rearrangement that activates the human RNA demethylase Alkbh5.
N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability.
N6-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression.
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia.
Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression.
Novel Small Molecule RNA m6A Demethylase AlkBH5 Inhibitors for Treating Cancer.
Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma.
Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors.
RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-?B pathway.
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
RNA epigenetic modification: N6-methyladenosine.
RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma.
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
The biological function of m6A demethylase ALKBH5 and its role in human disease.
The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance.
The Emerging Roles of RNA Modifications in Glioblastoma.
The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.
The N6 -methyladenosine (m6 A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma.
The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.
The role of N6-methyladenosine RNA methylation in the heat stress response of sheep (Ovis aries).
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Neoplasms, Germ Cell and Embryonal
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
Neuralgia
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Neuroinflammatory Diseases
m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity.
Obesity
Association of Metabolites with Obesity and Type 2 Diabetes Based on FTO Genotype.
Association of FTO rs1421085 with obesity, diet, physical activity, and socioeconomic status: A longitudinal birth cohort study.
Critical Enzymatic Functions of FTO in Obesity and Cancer.
Curcumin prevents obesity by targeting TRAF4-induced ubiquitylation in m6 A-dependent manner.
Erasing m6A-dependent transcription signature of stress-sensitive genes triggers antidepressant actions.
Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice.
FTO mRNA Expression in Extremely Obese and Type 2 Diabetic Human Omental and Subcutaneous Adipose Tissues.
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Human and Arabidopsis alpha-ketoglutarate-dependent dioxygenase homolog proteins-New players in important regulatory processes.
Identification of Specific N6-methyladenosine RNA Demethylase FTO Inhibitors by Single Quantum Dot-Based FRET Nanosensor.
Lose weight with traditional chinese medicine? Potential suppression of fat mass and obesity-associated protein.
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
mRNA m(6)A methylation downregulates adipogenesis in porcine adipocytes.
Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression.
Obesity and the brain: a possible genetic link.
Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m6A RNA Methylation.
RNA epigenetic modification: N6-methyladenosine.
Structural characteristics of small-molecule inhibitors targeting FTO demethylase.
The biology of FTO: from nucleic acid demethylase to amino acid sensor.
The fat mass and obesity-associated (FTO) gene: Obesity and beyond?
The RNA demethylase FTO is required for maintenance of bone mass and functions to protect osteoblasts from genotoxic damage.
The role of common and rare MC4R variants and FTO polymorphisms in extreme form of obesity.
Osteoporosis
Downregulated fat mass and obesity-associated protein inhibits bone resorption and osteoclastogenesis by nuclear factor-kappa B inactivation.
RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
Osteosarcoma
ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.
Ovarian Neoplasms
ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.
RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-?B pathway.
Pancreatic Neoplasms
ALKBH5 gene is a novel biomarker that predicts the prognosis of pancreatic cancer: A retrospective multicohort study.
ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation.
m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling.
m6A demethylase FTO suppresses pancreatic cancer tumorigenesis by demethylating PJA2 and inhibiting Wnt signaling.
RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Screening and Identifying m6A Regulators as an Independent Prognostic Biomarker in Pancreatic Cancer Based on The Cancer Genome Atlas Database.
The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells.
Peripheral Arterial Disease
Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Pre-Eclampsia
[ALKBH5 suppresses migration and invasion of human trophoblast cells by inhibiting epithelial-mesenchymal transition].
Prostatic Neoplasms
Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Pulmonary Disease, Chronic Obstructive
Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma.
The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
Reperfusion Injury
N6-methyladenosine demethylase FTO impairs hepatic ischemia-reperfusion injury via inhibiting Drp1-mediated mitochondrial fragmentation.
Squamous Cell Carcinoma of Head and Neck
Analysis of Genetic Alteration Signatures and Prognostic Values of m6A Regulatory Genes in Head and Neck Squamous Cell Carcinoma.
Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma.
Stomach Neoplasms
ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1.
Thyroid Diseases
Inclusion of ALKBH5 as a candidate gene for the susceptibility of autoimmune thyroid disease.
Thyroid Neoplasms
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.
M6A Demethylase FTO Plays a Tumor Suppressor Role in Thyroid Cancer.
Thyroiditis
Inclusion of ALKBH5 as a candidate gene for the susceptibility of autoimmune thyroid disease.
Urinary Bladder Neoplasms
ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2?-Mediated Glycolysis.
Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer.
Virus Diseases
Human and Arabidopsis alpha-ketoglutarate-dependent dioxygenase homolog proteins-New players in important regulatory processes.
N6-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication.
The RNA helicase DDX46 inhibits innate immunity by entrapping m(6)A-demethylated antiviral transcripts in the nucleus.
Wilms Tumor
ALKBH5 gene polymorphisms and Wilms tumor risk in Chinese children: A five-center case-control study.
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells.
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Zika Virus Infection
Dynamics of Human and Viral RNA Methylation during Zika Virus Infection.